levodopa/carbidopa fairmed
fairmed healthcare gmbh - levodopa/karbidopa - tabletės - 100 mg/25 mg - levodopa and decarboxylase inhibitor
levodopa/carbidopa fairmed
fairmed healthcare gmbh - levodopa/karbidopa - tabletės - 250 mg/25 mg - levodopa and decarboxylase inhibitor
gabapentin strides
strides pharma (cyprus) limited - gabapentinas - kietosios kapsulės - 100 mg - gabapentin
gabapentin strides
strides pharma (cyprus) limited - gabapentinas - kietosios kapsulės - 300 mg - gabapentin
gabapentin strides
strides pharma (cyprus) limited - gabapentinas - kietosios kapsulės - 400 mg - gabapentin
alfacalcidol strides pharma
strides pharma (cyprus) limited - alfakalcidolis - minkštosios kapsulės - 0,25 µg - alfacalcidol
alfacalcidol strides pharma
strides pharma (cyprus) limited - alfakalcidolis - minkštosios kapsulės - 0,5 µg - alfacalcidol
alfacalcidol strides pharma
strides pharma (cyprus) limited - alfakalcidolis - minkštosios kapsulės - 1 µg - alfacalcidol
kauliv
strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - kalcio homeostazė - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.
sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antinavikiniai vaistai - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.